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Abstract
Background: Pulmonary arterial hypertension (PAH) is one of the most relevant causes of death in systemic sclerosis.
The aims of this study were to analyse the recently published DETECT algorithm comparing it with European Society of
Cardiology/European Respiratory Society (ESC/ERS) 2009 guidelines: as screening of PAH; (2) identifying median
pulmonary arterial pressure (mPAP) ≥21 mmHg; and (3) determining any group of pulmonary hypertension (PH).
Methods: Eighty-three patients fulfilling LeRoy’s systemic sclerosis diagnostic criteria with at least right heart
catheterization were studied retrospectively. Clinical data, serological biomarkers, echocardiographic and hemodynamic
features were collected. SPSS 20.0 was used for statistical analysis.
Results: According to right heart catheterization findings, 35 patients with PAH and 28 with no PH met the
standards for DETECT algorithm analysis: 27.0% of patients presented with functional class III/IV. Applying
DETECT, the sensitivity was 100%, specificity 42.9%, the positive predictive value 68.6% and the negative
predictive value 100%, whereas employing the ESC/ERS guidelines these were 91.4%, 85.7%, 88.9% and 89.3%,
respectively. There were no missed diagnoses of PAH using DETECT compared with three patients missed (8.5%)
using ESC/ERS guidelines. The DETECT algorithm also showed greater sensitivity and negative predictive value
to identify patients with mPAP ≥21 mmHg or with any type of PH.
Conclusions: The DETECT algorithm is confirmed as an excellent screening method due to its high sensitivity
and negative predictive value, minimizing missed diagnosis of PAH. DETECT would be accurate either for early
diagnosis of borderline mPAP or any group of PH.
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Background
Systemic sclerosis (SSc) is an autoimmune disease charac-
terized by inflammation and autoimmunity, aberrant
tissue reparation with excessive extracellular matrix
deposition and altered vascular regeneration and endothe-
lial injury [1, 2]. Pulmonary arterial hypertension (PAH) is
one of the most severe complications in patients with SSc,
in whom the prevalence is 10% as diagnosed by right heart
catheterization (RHC) [3, 4]. PAH has a major negative
impact on survival and has become one of the leading
causes of SSc-related deaths [5–7]. The outcome of this
disease unfortunately is poor, with a 51% survival rate at
5 years of diagnosis even after the introduction of potent
vasodilatator agents [8]. Despite SSc being a well-known
risk factor for developing PAH, there are still delays in
diagnosing PAH and consequently more than 80% of
patients present with World Health Organization (WHO)
functional class III or IV at this point [8].
A French nationwide prospective multicentre study
aimed to compare early PAH diagnosis using Doppler
echocardiography prior to referral for RHC compared
with routine clinical practice [9]. Later, the authors dem-
onstrated prompt PAH identification in patients with
lower functional classes of disease and subsequently a
fourfold superior survival ratio [10]. The European
Society of Cardiology and the European Respiratory
Society (ESC/ERS) guidelines published in 2009 [11] rec-
ommended echocardiography in symptomatic patients.
RHC was carried out if the tricuspid regurgitant velocity
(TRV) was ≥3.4 m/s, TRV between 2.8-3.4 m/s with
symptoms or TRV ≤2.8 m/s with symptoms plus add-
itional echocardiographic variables suggestive of PH.
Recently, Coghlan et al. reported the first evidence-
based algorithm for the screening of PAH in SSc
(DETECT) [12]. The DETECT algorithm is a tool to iden-
tify patients with PAH in the asymptomatic stages,
through the study of clinical variables, pulmonary function
tests, immunological, biological, electrocardiographic and
finally echocardiographic parameters. The authors demon-
strated higher sensitivity of PAH detection than that
achieved using the ESC/ERS 2009 guidelines.
The main aim of this study was to determine the value
of the DETECT algorithm in a different population of
patients with SSc from that studied in the original work
and to compare it with the ESC/ERS 2009 guidelines.
Other objectives were to ascertain the ability of
DETECT to predict median pulmonary arterial pressure
(mPAP) ≥21 mmHg or to predict patients with pulmon-
ary hypertension (PH) versus patients with no PH.
Methods
Patients
Eighty-three patients with SSc who had undergone at
least one RHC were studied retrospectively. The RHC
was indicated due to suspicion of PAH after undergoing
an annual complete pulmonary function test and annual
echocardiography as routine monitoring of SSc. The rea-
sons for carrying out the RHC in our population were
the presence of right ventricular systolic pressure (RVSP)
>36 mmHg plus a forced vital capacity/diffusing capacity
for carbon monoxide (FVC/DLCO) ratio >1.6 in 35 pa-
tients, 34 patients had RVSP >36 mmHg, 8 patients had
a FVC/DLCO ratio >1.6 and 6 patients suffered exclu-
sively from progressive unexplained dyspnoea. All
patients fulfilled LeRoy’s SSc diagnostic criteria [13], and
80 patients also met the American College of
Rheumatology/European League Against Rheumatism
(ACR/EULAR) 2013 classification criteria [14]. The dur-
ation of disease was more than 3 years from the first
non-Raynaud’s phenomenon symptom in all cases. For
validation of the DETECT algorithm, four patients
were excluded as they presented with a FVC lower
than the 40% predicted value, and another patient
was excluded who did not meet the inclusion criteria
due to DLCO ≥60%.
Comparisons of the DETECT algorithm and the ESC/ERS
2009 guidelines
Three different scenarios were conducted for the com-
parison of the DETECT algorithm with the ESC/ERS
2009 guidelines: First, 35 patients diagnosed with PAH
and 28 with no PH after undergoing RHC were selected
for the application of the DETECT algorithm (see Fig. 1).
Second, these 63 patients were used to explore the cap-
acity of both screening tests to identify mPAP
≥21 mmHg (both borderline mPAP and PAH). Third,
with neither inclusion nor exclusion criteria 52 patients
diagnosed with PH and 31 with no PH were selected to
investigate the detection of any sort of PH.
Data collection
Data from the first available RHC of each patient were
revised. PH was defined as mPAP ≥25 mmHg in RHC,
and was classified in the following groups: WHO group
1 or PAH was defined if pulmonary artery wedge pres-
sure (PAWP) was ≤15 mmHg and pulmonary vascular
resistance (PVR) was >3 Wood units in RHC [15];
WHO group 2 or PH due to left heart disease, if PAWP
was >15 mmHg; WHO group 3 or PH due to interstitial
lung disease (ILD) if PAWP was ≤15 mmHg and pre-
dicted FVC <60% or if the extent of interstitial disease
was identified as moderate-severe on high-resolution
computed tomography (HRCT) [12]. Borderline mPAP
(BoPAP) was considered if mPAP was between 21 and
24 mmHg, with PAWP ≤15 mmHg and if there was no
ILD or the FVC was >60% [16].
Based on the extent of skin involvement, patients were
divided into those with diffuse cutaneous SSc (dcSSc) if
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thickening of the skin was distal and proximal to the
elbows or knees, limited cutaneous SSc (lcSSc) if the
affected skin did not exceed this limit proximally and
sine scleroderma systemic sclerosis (ssSSc) if no skin
thickening was present [17]. The disease onset was
described as the date of the first symptom attributable
to SSc, including Raynaud’s phenomenon (RP), although
the time from the first symptom excluding RP also was
analysed. All data were collected at the time of RHC.
The presence of telangiectasias, past or current digital
ulcers (DU) and past history of scleroderma renal crisis
(SRC) was recorded. ILD was defined as radiological evi-
dence of interstitial disease on HRCT. Cardiac involve-
ment was defined as current or past history of
pericardial effusion, left ventricular ejection fraction
(LVEF) <50% and ischaemic heart disease with no
cardiovascular risk factor or conduction abnormalities.
Antinuclear antibodies (ANA) were evaluated by indir-
ect immunofluorescence (IIF) assay using HEp-cell line
2. Anticentromere antibodies (ACA) were described by
IIF or commercial line blot assay to centromere proteins
A and B (EUROLINE Systemic Sclerosis (Nucleoli) Pro-
file (IgG), Euroimmun, Germany). Anti-topoisomerase I
antibodies were determined by enzyme-linked immuno-
sorbent assay.
Demographics, cardiovascular risk factors, anthropo-
metrical data, complete pulmonary function test (PFT),
6-minute walking distance (6MWD), WHO-functional
class, laboratory data including serum urate, N-terminal
pro-brain natriuretic peptide (NT-proBNP) and right
axis deviation in electrocardiography (ECG) were regis-
tered. Echocardiography included the determination of
left ventricular ejection fraction (LVEF), right atrium
(RA) area, tricuspid annular plane systolic excursion
(TAPSE), tricuspid regurgitation velocity (TRV) and
RVSP.
RHC details consisted of mPAP, PAWP, right atrial
pressure (RAP), transpulmonary pressure gradient
(TPG), cardiac output (CO), pulmonary vascular resist-
ance (PVR), systemic vascular resistance (SVR), mixed
venous oxygen saturation (SvO2) measured in pulmon-
ary artery and arterial oxygen saturation (SaO2) mea-
sured in arterial blood gas analysis.
The application of the DETECT algorithm was con-
ducted in two steps through the website PAH risk calcu-
lator (http://detect-pah.com) [18], the first step for
referring the patient for echocardiography and the sec-
ond for carrying out RHC [12]. The indication of RHC
following ESC/ERS 2009 guidelines was considered if:
(1) TRV was >3.4 m/s; or (2) TRV was >2.8 to ≤3.4 m/s,
Fig. 1 Flow of patients in the study population. Eighty-three patients with systemic sclerosis had at least one right heart catherization (RHC), which was
revised retrospectively. Four patients were excluded due to the exclusion criteria (all patients had forced vital capacity (FVC) <40%), and another patient
was excluded due to not meeting the inclusion criteria, who had a diffusing capacity for carbon monoxide (DLCO) ≥60%. Patients with pulmonary
arterial hypertension (PAH) and patients without pulmonary hypertension (no PH) (n= 63) were selected for the following studies: (1) validation of the
DETECT algorithm for screening of PAH and (2) identification of patients with median pulmonary arterial pressure (mPAP) ≥21 mmHg and (3)
determination of any group of PH (all patients (n= 83) were included in this study). WHOWorld Health Organization, PAWP pulmonary artery wedge
pressure, LHD left heart disease, ILD interstitial lung disease, HRCT high-resolution computed tomography
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with symptoms (undue dyspnoea or fatigue, chest pain,
near syncope or signs of right heart failure); or (3) TRV
was ≤2.8 m/s, with symptoms and additional echocar-
diographic variables suggestive of PH.
Statistical analysis
Qualitative data were expressed as the mean and stand-
ard deviation (SD) after checking the data using the
normal distribution test, and non-normally distributed
qualitative variables were described as the median and
interquartile range (IQR). To assess whether there were
statistically significant differences, Student’s t test or
the Mann-Whitney U test were used according to the
result of the normal distribution test. Categorical
variables were analysed by the chi-square test and
Fisher’s exact test. The 95% confidence intervals (CIs)
were calculated for sensitivity, specificity, positive pre-
dictive value (PPV) and negative predictive value
(NPV). A p value <0.05 was considered significant. Stat-
istical analysis was conducted using SPSS 20.0 for Win-
dows (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics
Comparing the indications for RHC in 83 patients, the
proportions of patients diagnosed with PH were 24/35
patients (68.5%) with RVSP >36 mmHg plus FVC/DLCO
ratio >1.6, 23/34 patients (67.6%) with RVSP >36 mmHg,
4/8 patients (50.0%) with FVC/DLCO ratio >1.6 and 1/6
patients (16.6%) with progressive unexplained dyspnoea.
Two the four patients who were excluded had PH due
to ILD. Following the RHC results in the 78 patients
who fulfilled the inclusion criteria and did not meet the
exclusion criteria, PH was identified in 50 patients
(64.1%) and PH was ruled out in the other 28 subjects
(35.8%), although 14 of them had BoPAP with mPAP be-
tween 21 and 24 mmHg (Fig. 1). According to PH classi-
fication, 35 patients (44.8%) were diagnosed with PAH, 6
(7.6%) had PH due to left heart disease and 9 (11.5%)
had PH due to ILD. Sixty-three patients with PAH and
without PH were selected for DETECT algorithm
analysis.
The baseline characteristics of the selected patients
with SSc are summarized in Table 1. There were 59
women and 4 men, the mean ± SD age at RHC was 62.4
± 11.6 years. Based on skin involvement, lcSSc was the
most frequent cutaneous subtype in 45 patients (71.4%),
10 patients (15.9%) had dcSSc and 8 patients (12.7%)
had ssSSc. The mean time from the first SSc symptom
including RP was 18.6 ± 12.3 years, while for the time
from first non-RP it was 10.5 ± 8.9 years. Almost the
whole study population (n = 61 (96.8%)) fulfilled the
ACR/EULAR 2013 classification criteria. There were no
statistical differences in the presence of telangiectasias,
past or current DU, history of SRC, ILD or cardiac in-
volvement, when comparing the two groups. Although
there were no statistical differences in positivity to anti-
nuclear antibodies or the observation of a nucleolar pat-
tern in the indirect immunofluorescence, patients with
PAH more often had ACA (n = 23, 65.7% vs n = 11,
39.3%, p = 0.03), but lower positivity against anti-
topoisomerase I antibodies (n = 3, 8.6% vs n = 9, 32.1%,
p = 0.01). Arterial hypertension was the most frequent
cardiovascular risk factor in the whole group, being
identified in 27 patients (42.9%), followed by dyslipidae-
mia in 15 patients (23.8%); however, there were no pa-
tients with diabetes mellitus. No statistical differences
were identified in the anthropometrical variables. The
patients with PAH received less immunosuppressant
therapy than the control group, and less treatment with
calcium channel blockers. However, there were no statis-
tical differences in the use of specific vasodilator ther-
apy, for which the indication was RP in all cases.
Regarding respiratory parameters, the PAH group had
higher FVC percent predicted/DLCO percent predicted
than controls (2.0 ± 0.7% vs 1.5 ± 0.4%, p < 0.01) and
shorter 6MWD (232.8 ± 76.7 m vs 322.4 ± 105.0 m,
p = 0.01) (Table 2). Advanced WHO functional
classes III/IV were more common in patients with PAH
(n = 15 (42.9%)), than in the group with no PH (n = 2
(7.1%)) (p < 0.01). There were higher NT-proBNP and
serum urate levels and higher prevalence of right axis devi-
ation on ECG in the PAH group. In relation to echocardio-
graphic data, patients with PAH had a greater RA area;
moreover, they presented with higher TRV and RVSP than
patients with no PH. Therefore, there were statistically sig-
nificant differences between PAH and without PH patients
in seven out of eight variables considered in DETECT
algorithm.
RHC in the PAH group was characterized by superior
mean PAP (Table 3). Specifically, the median (IQR) of
mPAP was 42.0 (33.0 − 50.0) mmHg in patients with
PAH, while it was 20.5 (17.0 to 23.0) mmHg in the
group with no PH (p < 0.001). Furthermore, TPG was in-
creased in patients with PAH, but CO was lower in
those patients. The PAH group had higher pulmonary
vascular resistance, with lower SvO2 and SaO2 during
the RHC, compared with the group with no PH.
Comparisons of the DETECT algorithm and the ESC/ERS
2009 guidelines
The DETECT algorithm steps are represented in Table 4.
After step 1 of the algorithm 35 patients in the PAH group
(100%) would have been referred to echocardiography
compared to 24 in the group without PH (85.7%) (p =
0.03). Following the echocardiography results, RHC would
have been recommended in all 35 patients in the PAH
group (100%), while this was only the case in 16
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subjects (57.1%) in patients with no PH (p < 0.001).
However, based on the ESC/ERS 2009 guidelines, 32
patients with PAH (91.4%) and 4 patients in the
group without PH (14.3%) would have been referred
for RHC. The RHC referral ratio was higher using
DETECT than it was using the ESC/ERS guidelines.
The main reasons for not referring these patients for
RHC using the ESC/ERS 2009 guidelines would have
been that 12 patients had TRV >2.8 to ≤3.4 m/s but
with no symptoms, 5 patients presented with TRV
≤2.8 m/s with symptoms but with no additional echo-
cardiographic signs of PH, and another 10 patients
had TRV ≤2.8 m/s with no symptoms and no add-
itional echocardiographic signs of PH. There would
have been no missed diagnosis of PAH with DETECT,
but using the ESC/ERS guidelines it would have
reached 8.5% (Table 5). The sensitivity (95% CI) of
the DETECT algorithm was 100% (90.1–100) com-
pared to sensitivity of 91.4% (77.6–97.0) using the
ESC/ERS 2009 guidelines. The specificity was lower
with DETECT at 42.9% (26.5–60.9) whereas it was
85.7% (68.2–94.3) using the ESC/ERS 2009 guidelines.
No statistical differences were found in PPV, which
was 68.6% (55.0–79.7) using DETECT compared to
88.9% (74.7–95.6) using the ESC/ERS 2009 guidelines.
However, NPV reached 100% (75.7–100) using the
DETECT algorithm, while using the ESC/ERS 2009
guidelines it was 88.9% (71.9–96.1).








Femalea 59 (93.7) 34 (97.1) 25 (89.3) 0.31
Age, yearsb 62.4 (±11.6) 64.4 (± 10.8) 59.9 (± 12.4) 0.13
DcSSca 10 (15.9) 4 (11.4) 6 (21.4) 0.31
Time from first symptom, yearsb 18.6 (± 12.3) 19.6 (±11.2) 17.2 (± 13.7) 0.29
Time from first non-RP symptom, yearsb 10.5 (± 8.9) 9.7 (±9.4) 11.5 (± 8.2) 0.21
ACR/EULAR 2013 classification criteriaa 61 (96.8) 34 (97.1) 27 (96.4) 1.0
Telangiectasiasa 59 (93.7) 33 (94.3) 26 (92.9) 1.0
Digital ulcersa 35 (55.6) 20 (57.1) 15 (53.6) 0.77
Scleroderma renal crisisa 2 (3.2) 2 (5.7) 0 (0) 0.49
Interstitial lung diseasea 32 (50.8) 19 (54.3) 12 (42.9) 0.45
Cardiac involvementa 26 (41.3) 17 (48.6) 9 (32.1) 0.18
Antinuclear antibodiesa 62 (98.4) 34 (97.1) 28 (100) 1.0
ACAa 34 (54.0) 23 (65.7) 11 (39.3) 0.03
Anti-Scl-70a 12 (19.0) 3 (8.6) 9 (32.1) 0.01
Nucleolar IIF patterna 4 (6.3) 3 (8.6) 1 (3.6) 0.62
Arterial hypertensiona 27 (42.9) 14 (40) 13 (43.4) 0.60
Dyslipidaemiaa 15 (23.8) 6 (17.1) 9 (32.1) 0.16
Diabetes mellitusa 0 (0) 0 (0) 0 (0) NA
Immunosuppressant therapya 25 (39.7) 8 (22.9) 17 (60.7) <0.01
Prednisonea 19 (30.2) 7 (20.0) 12 (40.9) 0.04
Sodium mycophenolatea 7 (11.1) 1 (2.9) 6 (21.4) 0.03
Azathioprine 3 (4.8) 0 (0) 3 (10.7) 0.08
IV cyclophosphamidea 12 (19.0) 3 (8.6) 9 (32.1) 0.01
Calcium channel blockera 33 (52.4) 14 (40.0) 19 (67.9) 0.02
Specific vasodilator therapya 13 (20.6) 7 (20.0) 6 (21.4) 0.88
IV prostanoidsa 1 (1.6) 1 (2.9) 0 (0) 1.0
ERAa 10 (15.9) 5 (14.3) 5 (17.9) 0.74
PDE5 Ia 5 (7.9) 2 (5.7) 3 (10.7) 0.64
PAH pulmonary arterial hypertension, PH pulmonary hypertension, dcSSc diffuse cutaneous systemic sclerosis, ACR/EULAR American College of Rheumatology/
European League Against Rheumatism, RP Raynaud’s phenomenon, ACA anticentromere antibodies, IIF indirect immunofluorescence, NA not applicable, IV
intravenous, ERA endothelin receptor antagonist, PDE5 I phosphodiesterase type-5 inhibitor. aData are shown as number (%) for categorical variables. bData are
shown as mean (± SD)
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As a strategy to identify mPAP ≥21 mmHg (both
BoPAP and PAH), the DETECT algorithm had superior
sensitivity of 93.9% (83.5–97.9) and NPV of 75.0%
(46.8–91.1) compared to ESC/ERS guidelines for which
the sensitivity and NPV was 69.4% (55.5–80.5) and
44.4% (27.6–62.7), respectively. Furthermore, DETECT
missed 6.1% of diagnoses of mPAP ≥21, whereas using
the ESC/ERS 2009 guidelines the percentage was in-
creased to 30.6%. In fact, analysing only patients with
BoPAP, there were 3 out of 14 (21.1%) missed diagnoses
using DETECT, whereas there were 12 out of 14 (85.7%)
missed using the ESC/ERS 2009 guidelines. However,
specificity and PPV were slightly lower using the
DETECT algorithm, at 64.3% and 90.2% compared to
85.7% and 94.4%, respectively, using the ESC/ERS
guidelines.
To investigate the capacity for the detection of any
type of PH, the whole cohort of patients (n = 83) with a
first RHC were studied, regardless of whether they met
the inclusion or exclusion criteria for application of the
DETECT algorithm: 1.9% of diagnoses of PH were
missed using the DETECT algorithm compared with









FVC, % predictedb 75.2 (± 16.4) 75.6 (± 15.5) 74.7 (± 17.8) 0.86
DLCO, % predictedb 46.3 (± 14.2) 41.5 (± 13.9) 51.0 (± 13.1) 0.01
FVC%/DLCO%b 1.8 (± 0.6) 2.0 (± 0.7) 1.5 (± 0.4) <0.01
6MWD, mb 256.5 (± 92.5) 232.8 (± 76.7) 322.4 (± 105.0) 0.01
WHO functional class III/IVa 17 (27.0) 15 (42.9) 2 (7.1) <0.01
Laboratory
NT-proBNP, pg/mLc 198 (41 to 647) 1271 (580 to 3154) 87 (32 to 202) <0.001
Serum urate, mg/dLb 5.6 (± 1.9) 6.8 (± 1.9) 4.6 (± 1.0) <0.001
Right axis in ECGa 18 (28.6) 10 (28.6) 1 (3.6) 0.01
Echocardiography
LVEF, %c 60.0 (59.0 to 65.0) 60.0 (58.5 to 65.0) 62.0 (59.7 to 65.0) 0.43
TAPSE, mmb 19.4 (± 3.9) 19.1 (± 4.6) 19.8 (± 3.0) 0.55
RA area, cm2c 16.0 (13.0 to 21.0) 17.0 (15.0 to 22.7) 14.0 (12.0 to 16.0) <0.01
TRV, m/sb 3.5 (± 0.7) 4.0 (± 0.6) 2.8 (± 0.3) <0.001
RVSP, mmHgc 59.5 (44.0 to 76.2) 73.0 (61.0 to 85.0) 44.0 (37.0 to 51.0) <0.001
PAH pulmonary arterial hypertension, PH pulmonary hypertension, FVC forced vital capacity, DLCO diffusing capacity for carbon monoxide, 6MWD 6-minute
walking distance, WHO World Health Organization, NT-proBNP N-terminal pro-brain natriuretic peptide, ECG electrocardiography, LVEF left ventricular ejection
fraction, TAPSE tricuspid annular plane systolic excursion, RA right atrium, TRV tricuspid regurgitant velocity, RVSP right ventricular systolic pressure. aData are
shown as number (%) for categorical variables. bData are shown as mean (± SD). cData are shown as median (IQR)








Mean PAP, mmHgb 31.0 (21.0 to 44.0) 42.0 (33.0 to 50.0) 20.5 (17.0 to 23.0) <0.001
PAWP, mmHga 9.6 (± 4.0) 9.7 (± 4.8) 9.5 (± 3.4) 0.90
RAP, mmHgb 5.0 (2.5 to 8.5) 5.0 (3.0 to 10.0) 4.5 (2.0 to 7.0) 0.14
TPG, mmHga 20.0 (± 13.4) 31.4 (± 11.8) 10.6 (± 3.9) <0.001
Cardiac output, L/minb 3.5 (2.9 to 4.5) 3.4 (2.8 to 4.0) 3.9 (2.9 to 5.1) 0.05
PVR, WUa 6.6 (± 4.8) 9.9 (± 4.6) 3.2 (± 1.6) <0.001
SVR, WUa 26.9 (± 10.3) 28.6 (± 9.7) 25.2 (± 11.0) 0.42
SvO2, %a 66.3 (± 8.1) 61.8 (± 8.3) 71.0 (± 4,7) <0.001
SaO2, %a 93.5 (± 4.0) 91.2 (± 3.7) 96.1 (± 2.5) <0.001
PAH pulmonary arterial hypertension, PH pulmonary hypertension, PAP pulmonary artery pressure, PAWP pulmonary artery wedge pressure, RAP right atrial
pressure, TPG transpulmonary pressure gradient, PVR pulmonary vascular resistance, WU Wood units, SVR systemic vascular resistance, SvO2 mixed venous oxygen
saturation, SaO2 arterial oxygen saturation. aData are shown as mean (± SD). bData are shown as median (IQR)
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19.2% missed using the ESC/ERS 2009 guidelines. More-
over, sensitivity and NPV were greater at 98.1% and
93.3% using the DETECT method, compared with 80.8%
and 73.0%, respectively, using the ESC/ERS guidelines.
Nevertheless, specificity and PPV were again slightly in-
ferior at 45.2% and 75.0% when applying the DETECT
algorithm, whereas the values were 87.1% and 91.3%,
respectively, using in the ESC/ERS guidelines.
Discussion
The present retrospective study compared the applica-
tion of the DETECT algorithm with the ESC/ERS 2009
guidelines in patients with PAH and patients without
PH, who had undergone RHC. The DETECT
programme had greater sensitivity, the RHC would have
been recommended in all patients suffering from PAH,
and also superior NPV compared to the ESC/ERS guide-
lines. Nevertheless, the ESC/ERS 2009 guidelines had
higher specificity and PPV than the DETECT algorithm.
Furthermore, the DETECT algorithm had higher per-
centage sensitivity and NPV both for the detection of
patients with mPAP ≥21 and for patients with any type
of PH, although specificity and PPV were lower.
For the application of the DETECT algorithm it is ne-
cessary to meet the inclusion criteria, so patients must
present with a duration of SSc longer than 3 years from
the first non-RP symptom and DLCO <60% predicted.
This was to increase the specificity of the screening
method, due to the fact that <10% of a cohort of 243 pa-
tients with SSc-PH have been found to present with
DLCO >60% [19]. Furthermore, patients could not fulfil
the exclusion criteria such as previous PH diagnosed by
RHC, forced vital capacity (FVC) <40% or the involve-
ment of left heart disease [12]. Nevertheless, DETECT
does not establish the periodicity of an assessment by
this method, it has not been evaluated over a monitoring
period in a cohort of patients and its ability to predict
mPAP ≥21 mmHg or any type of PH have not been ex-
plored. As a consequence of this work, the new ESC/
ESR 2015 guidelines were recently published, which
strengthen the recommendation for annual screening of
PH in this set of patients with SSc and introduce the
Table 4 Comparisons of the DETECT algorithm and the ESC/ERS 2009 guidelines
PAH vs no PH patients
(n = 63)
Patients with mPAP ≥21 vs mPAP <21mmg
(n = 63)
















Score step 1b 330.0 (±25.3) 313.7 (±17.5) <0.01 326.9 (±22.8) 308.6 (±20.8) <0.01 327.9 (±23.6) 311.8 (±17.6) <0.01
Indication of Echoa 35 (100) 24 (85.7) 0.03 49 (100) 10 (71.4) <0.01 51 (98.1) 24 (77.4) <0.01
Score step 2b 60.2 (±11.3) 37.3 (±8.4) <0.001 54.7 (±13.3) 33.5 (±8.8) <0.001 56.4 (±12.4) 36.5 (±8.4) <0.001
RHC recommendationa 35 (100) 16 (57.1) <0.001 46 (93.9) 5 (35.7) <0.001 51 (98.1) 17 (54.8) <0.001
ESC/ERS 2009 guidelines
RHC recommendationa 32 (91.4) 4 (14.3) <0.001 34 (69.4) 2 (14.3) <0.001 42 (80.8) 4 (12.9) <0.001
PAH pulmonary arterial hypertension, PH pulmonary hypertension, mPAP mean pulmonary artery pressure, Echo echocardiography, RHC right heart catheterization,
ESC/ERS European Society of Cardiology and the European Respiratory Society. aData are shown as number (%) for categorical variables. bData are shown as mean (± SD)
Table 5 Observation of PAH detection programs
RHC referral rate, % Missed diagnoses, % Sensitivity % Specificity % PPV % NPV %






















































































Data shown as number (%). RHC right heart catheterization, PPV positive predictive value, NPV negative positive value, PAH pulmonary arterial hypertension,
PH pulmonary hypertension, CI confidence interval, mPAP mean pulmonary artery pressure, ESC/ERS European Society of Cardiology and the European
Respiratory Society
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DETECT algorithm as a valid method to be performed
in this group of patients based on the evidence demon-
strated [15].
Compared to the study of Coghlan et al., patients in
our cohort had a surprisingly higher prevalence of telan-
giectasias and ACA antibodies. Almost 60% of patients
with PAH presented with WHO functional class I or II
and mild reduced 6MWD comparable to the detection
cohorts of previous studies that have focused on early
PAH diagnosis [10, 12]. This fact seems to reflect that
patients in our study were referred promptly for RHC as
a result of active and early suspicion of PAH during
monitoring. In the present paper we describe similar
sensitivity, specificity and NPV values, although with a
higher RHC referral ratio and PPV using the DETECT
algorithm than in the original work. However, regarding
the application of ESC/ERS 2009 guidelines we report
higher sensitivity, specificity and PPV values and a
higher RHC referral ratio than Coghlan et al. This may
be explained due to the fact that the main indication for
performing RHC in our study was the presence of an ab-
normal echocardiographic result, suggesting the pres-
ence of PAH. Furthermore, the high RHC referral ratio
may be justified because the study was conducted in a
selected population of patients at high risk of PAH based
on clinical, pulmonary function test and echocardio-
graphic parameters.
Few groups have published on the application of the
DETECT algorithm. Hao et al. analysed the DETECT al-
gorithm in patients from the multicentre Australian
Scleroderma Cohort Study (ASCS) along with the
Australian Scleroderma Interest Group (ASIG)
algorithm and the ESC/ERS 2009 guidelines [20, 21].
The authors found higher sensitivity and NPV using the
DETECT or the ASIG algorithm than they did using the
ESC/ERS guidelines, which we can confirm in our study.
Surprisingly, the ASIG protocol had superior specificity
to the DETECT algorithm and even to the ESC/ERS
guidelines, which contrasts with the values of 48% and
69%, respectively, that were previously published [12].
The authors reported that nine patients did not meet
the criterion of DLCO <60% or the criterion for disease
duration, and this may explain the lower specificity of
the DETECT algorithm [21]. Furthermore, the DETECT
and ASIG screening methods had the highest sensitivity
and specificity to identify both precapillary PH and any
group of PH, results that we have corroborated in our
work. In the present work the ASIG programme was not
analysed due to the fact that this method is not based on
evidence and has not been well-validated in European
cohorts.
Recently, a Czech scleroderma group designed a modi-
fied DETECT algorithm, in which a right ventricular
outflow tract is evaluated instead of RA area [22]. Using
this modified DETECT programme the RHC referral ra-
tio was 41.4% compared to 24.1% using the ESC/ERS
guidelines. Interestingly, although only 11/58 patients
(18.9%) had undergone RHC, in patients who were rec-
ommended by the modified DETECT algorithm there
were also other types of PH diagnosed, such as PH due
to left heart disease and PH due to ILD. Therefore, this
article suggests that the DETECT algorithm would be
useful for recommending RHC for diagnosing other
types of PH according to the WHO classification.
Although there are some discrepancies on the prog-
nostic role of BoPAP, a study has been recently pub-
lished evidencing a higher risk of mortality and
hospitalization in US veteran patients with BoPAP
(defined as 19–24 mmHg) [23]. Consequently, the
study highlights the relevance of diagnosing BoPAP in
selected groups of patients such as those with sclero-
derma. In a post-hoc analysis of the DETECT study, the
authors demonstrated that patients with BoPAP had a
higher FVC/DLCO rate, and higher TRV and NT-
proBNP levels than in patients with normal mPAP [16].
Although the paper does not evaluate the application of
DETECT in both groups of patients, it would support
the increment of the specificity of this programme
identified in our work when studying patients with
mPAP ≥21 versus mPAP <21mmg, compared to the
PAH versus no PH strategy. In the set of patients with
SSc, identifying BoPAP in the first RHC was demon-
strated as a high risk factor for developing PH, with a
hazard ratio of 3.7 during follow up compared to pa-
tients with mPAP <21 mmHg [24]. In this line, in a
multicentre prospective SSc cohort, the Pulmonary
Hypertension Assessment and Recognition of Out-
comes in Scleroderma (PHAROS) study group reported
that 55% of patients with BoPAP progressed to PH,
whereas in the group of patients with mPAP <21 mmHg
this was 32%, over a mean 25.7-month period of moni-
toring [25]. Having established the relevance of identi-
fying patients with SSc and BoPAP for close
supervision, this is the first paper that demonstrates the
accuracy of the DETECT algorithm in the identification
of patients with mPAP ≥21.
The main limitation of the present study was the
retrospective design. RHC was not performed in the
whole cohort of patients with SSc, therefore some mild
forms of PAH may have been undiagnosed. In the same
line, although the periodicity of performing the screen-
ing methods is not well established, these were not
carried out in the whole cohort, which may not reflect
the real referral rate for RHC.
Conclusions
Pulmonary arterial hypertension in one of the leading
causes of death in patients with SSc, and its early
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diagnosis has demonstrated increased survival rates. The
present study supports the DETECT algorithm as an ex-
cellent screening method due to its high sensitivity and
NPV, which minimizes the number of missed diagnoses
of previous recommendations. Furthermore, our data
suggest the DETECT algorithm is also accurate either
for an early diagnosis of borderline mPAP, patients who
are at highest risk of developing PAH, or the diagnosis
of any type of PH.
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